Byetta

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
Fri, 09/27/19 - 09:10 am
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
Tue, 07/24/18 - 10:32 am
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Next stop in AstraZeneca fire sale: China
BioPharma Dive
Thu, 10/13/16 - 03:27 pm
AstraZeneca
China
Byetta
Bydureon
Teva seals deal to market copy of AstraZeneca diabetes drug
BioPharma Dive
Sat, 06/25/16 - 01:47 pm
Teva Pharmaceutical
AstraZeneca
Byetta
generics
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States
Yahoo
Thu, 06/23/16 - 09:22 am
Teva Pharmaceuticals
patents
AstraZeneca
Byetta
AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports
Fierce Pharma
Tue, 06/16/15 - 12:08 pm
diabetes
side effects
heart failure
pancreatitis
Nesina
Takeda
Onglyza
AstraZeneca
Farixga
Byetta
Victoza
Januvia
Merck
Novo Nordisk
AstraZeneca Posts Positive Data on its Type II Diabetes Drug
Yahoo/Zacks.com
Wed, 09/24/14 - 08:00 am
AstraZeneca
diabetes
Byetta
exenatide
FDA eases worries regarding certain diabetes medications
Yahoo/Fly on the Wall
Thu, 02/27/14 - 08:19 am
FDA
diabetes
Merck
Januvia
Janumet
Novo Nordisk
Victoza
Bristol-Myers Squibb
Byetta
Bydureon
Are These Diabetes Drugs Safe After All?
Motley Fool
Thu, 08/1/13 - 09:17 am
Januvia
Merck
Byetta
Bristol-Myers Squibb
diabetes
type 2 diabetes
Diabetes Drugs’ Pancreas Risk Not Backed by Evidence: EMA
Bloomberg
Fri, 07/26/13 - 09:03 am
diabetes
Europe
Byetta
Bristol-Myers Squibb
Merck
Januvia
GLP-1 agonist
Novo Nordisk
Victoza
New GSK diabetes drug works, but faces tough competition
Reuters
Mon, 06/24/13 - 10:28 am
GSK
diabetes
albiglutide
GLP-1 agonist
Victoza
Byetta
Bydureon
Novo Nordisk
Bristol-Myers Squibb
AstraZeneca
Diabetes Drugs Under Scrutiny As FDA Considers Another Study
Pharmalot
Wed, 06/12/13 - 12:40 pm
FDA
diabetes
Merck
Januvia
Onglyza
Bristol-Myers Squibb
Byetta
AstraZeneca
Eli Lilly
Novo Nordisk
Victoza
Tradjenta
Boehringer Ingelheim
Doctor’s Doubts Imperil Lucrative Diabetes Drugs
NY Times, NY
Thu, 05/30/13 - 04:51 pm
physicians
diabetes
Bristol-Myers Squibb
Byetta
Merck
AstraZeneca
Januvia
Novo Nordisk
Eli Lilly
Takeda
Boehringer Ingelheim
Johnson & Johnson's New Diabetes Drug And Its Competitors
Seeking Alpha
Tue, 04/2/13 - 09:52 am
JNJ
diabetes
Invokana
Merck
Januvia
Byetta
Bristol-Myers Squibb
Diabetes Drugs Are Being Evaluated for Pancreatic Risk
Bloomberg
Thu, 03/14/13 - 11:15 am
pancreatic cancer
diabetes
Merck
Januvia
Bristol-Myers Squibb
Byetta
Novo Nordisk
Victoza
Merck, Bristol Diabetes Drugs Linked to Pancreatitis Risk
Bloomberg
Tue, 02/26/13 - 10:04 am
Merck
diabetes
Bristol-Myers Squibb
pancreatitis
Januvia
Byetta
FDA: Amylin Pharma Concealed Heart Safety Risks of Key Diabetes Drug
TheStreet.com
Mon, 06/25/12 - 03:29 pm
FDA
Amylin
Byetta
diabetes
Novo's Victoza Leads To Greater Weight Loss Than Byetta
Bloomberg
Mon, 06/11/12 - 10:47 am
Byetta
diabetes
Victoza
Novo Nordisk
Amylin
Byetta Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes
Yahoo/Business Wire
Sat, 06/9/12 - 12:31 pm
Byetta
Amylin
diabetes
type 2 diabetes
Lilly, Amylin receive European approval for expanded use of diabetes treatment Byetta
Yahoo/AP
Fri, 03/23/12 - 11:27 am
Eli Lilly
Amylin
Europe
diabetes
Byetta

Pages